Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500319 | 1.00 | FNTA (0.71) | FNTAFNTB | |
| SCHEMBL3500321 | 1.00 | FNTA (0.71) | FNTAFNTB | |
| SCHEMBL3499828 | 0.95 | FNTA (0.63) | FNTAFNTB | |
| SCHEMBL6636817 | 0.95 | FNTA (0.63) | FNTAFNTB | |
| SCHEMBL3500027 | 0.92 | FNTA (0.65) | FNTAFNTB | |
| SCHEMBL3500024 | 0.92 | FNTA (0.65) | FNTAFNTB | |
| SCHEMBL3499855 | 0.92 | FNTA (0.71) | FNTAFNTB | |
| SCHEMBL3503177 | 0.92 | FNTA (0.59) | FNTAFNTB | |
| SCHEMBL3500707 | 0.91 | FNTA (0.59) | FNTAFNTB | |
| SCHEMBL3500712 | 0.91 | FNTA (0.59) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481975-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-01 | — | — | EP | claimed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | claimed |
| EP-1143796-A4 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-BETA-CYCLODEXTRIN OR 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2002-03-20 | — | — | EP | claimed |
| EP-1143796-A1 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-BETA-CYCLODEXTRIN OR 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-17 | — | — | EP | claimed |
| US-6218375-B1 | AS ANTI-TUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2001-04-17 | — | — | US | claimed |
| WO-2000042849-A1 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD | BRISTOL-MYERS SQUIBB CO. (US) | 2000-07-27 | — | — | WO | claimed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2010057028-A9 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| WO-2010057028-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| EP-1143796-A4 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-BETA-CYCLODEXTRIN OR 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-1143796-A1 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-BETA-CYCLODEXTRIN OR 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6218375-B1 | AS ANTI-TUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000042849-A1 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD | BRISTOL-MYERS SQUIBB CO. (US) | 2000-07-27 | — | — | WO | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0892797-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997030992-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | FNTA 19/4885FNTB 24/4885 |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | FNTA 1/4885FNTB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.